Recent regulatory activities highlight both opportunities and challenges in the competitive landscape. FDA's complete response letter for bevacizumab-vikg demonstrates regulatory scrutiny for biosimilar and reformulated products. Extended review timelines for Eylea HD applications reflect manufacturing complexities for next-generation formulations. The discontinuation of sozinibercept development underscores clinical and commercial risks in competitive markets while validating the difficulty of achieving differentiation in established therapeutic areas.